First phase study

The second part of our 1st phase study has just been successfully completed with no Serious Adverse Events.

Drug administration was performed on ECU, where Subjects were provided with carefull medical care. As a standard, Team of Specialists (Anesthesiologist, Psychiatrist, two Investigators and Nurses) was present during the procedure just to assure maximum safety and quality of recorded data. Vital signs of the Subjects were constantly monitored (BP holter and ECG monitoring) and assessed by a Physician.

Go back

News

Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers

In BRG we are just starting Study for Healthy People with an Immune Drug - Part B. The aim of the following clinical trial...

Read more …

Merry Christmas and Happy New Year

Let the magical night of Christmas Eve bring peace and joy. Let every moment of Christmas live with its own beauty, and bestows the New Year with prosperity and happiness.

Read more …

COVID -19 Antigen Tests:

On 31st of October 2020, the Chief Sanitary Inspectorate confirmed that the antigen cassette tests are the same basis for determining the SARS-CoV-2 ...

Read more …

BRG team participated in BIO-Europe®

On 26th -27th  of October BRG team participated in BIO-Europe® the largest partnering conference in Europe dedicated to the global biotechnology industry. 

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2021 © Bio Research Group. All rights reserved.

 

scroll to top ▲